Commentary|Articles|July 15, 2026

Kerry Rogers, MD, Talks BTK Inhibitor Sequencing, Cost, Access in CLL

Author(s)Maggie L. Shaw, Kerry Rogers, MD

Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).

The evolving Bruton tyrosine kinase (BTK) inhibitor landscape for chronic lymphocytic leukemia (CLL) is reshaping how clinicians counsel patients, not just on treatment selection but also on the realities of staying on therapy for years and the systemic challenges that determine who can access care, said Kerry Rogers, MD, associate professor at The Ohio State University Comprehensive Cancer Center–The James.